Norge - norsk - Statens legemiddelverk

sandoz a/s - Østradiolhemihydrat - depotplaster - 25 mikrog/24 timer

Norge - norsk - Statens legemiddelverk

sandoz a/s - Østradiolhemihydrat - depotplaster - 37.5 mikrog/24 timer

Norge - norsk - Statens legemiddelverk

sandoz a/s - Østradiolhemihydrat - depotplaster - 50 mikrog/24 timer

Norge - norsk - Statens legemiddelverk

sandoz a/s - Østradiolhemihydrat - depotplaster - 75 mikrog/24 timer

Norge - norsk - Statens legemiddelverk

sandoz a/s - Østradiolhemihydrat - depotplaster - 100 mikrog/24 timer

Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Norge - norsk - Statens legemiddelverk

novo nordisk a/s - Østradiolhemihydrat - vaginaltablett - 10 mikrog

Norge - norsk - Statens legemiddelverk

viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 2 mg / 10 mg

Norge - norsk - Statens legemiddelverk

viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 1 mg / 10 mg

Norge - norsk - Statens legemiddelverk

viatris healthcare ltd. - Østradiolhemihydrat / dydrogesteron - tablett, filmdrasjert - 1 mg / 5 mg